Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Trials
; 20(1): 57, 2019 Jan 16.
Article
in En
| MEDLINE
| ID: mdl-30651149
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oxazoles
/
Pyrazinamide
/
Tuberculosis, Pulmonary
/
Tuberculosis, Multidrug-Resistant
/
Drug Resistance, Multiple, Bacterial
/
Levofloxacin
/
Linezolid
/
Mycobacterium tuberculosis
/
Nitroimidazoles
/
Antitubercular Agents
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Guideline
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
Trials
Journal subject:
MEDICINA
/
TERAPEUTICA
Year:
2019
Document type:
Article
Country of publication: